Satraplatin
- Generic Name
- Satraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C10H22Cl2N2O4Pt
- CAS Number
- 129580-63-8
- Unique Ingredient Identifier
- 8D7B37T28G
- Background
Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.
- Indication
Investigated for use/treatment in lung cancer, prostate cancer, and solid tumors.
A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel
- Conditions
- TumorsProstate Cancer
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2012-05-10
- Lead Sponsor
- Agennix
- Target Recruit Count
- 25
- Registration Number
- NCT00313456
- Locations
- ๐บ๐ธ
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- Agennix
- Target Recruit Count
- 40
- Registration Number
- NCT00268970
- Locations
- ๐บ๐ธ
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Satraplatin for Patients With Metastatic Breast Cancer (MBC)
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2012-03-28
- Lead Sponsor
- Agennix
- Target Recruit Count
- 40
- Registration Number
- NCT00265655
- Locations
- ๐บ๐ธ
US Oncology, Dallas, Texas, United States
Study of Satraplatin (JM-216) in Combination With Docetaxel
- Conditions
- Tumors
- First Posted Date
- 2005-08-01
- Last Posted Date
- 2012-03-26
- Lead Sponsor
- Agennix
- Target Recruit Count
- 28
- Registration Number
- NCT00125411
- Locations
- ๐บ๐ธ
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy
- First Posted Date
- 2004-10-04
- Last Posted Date
- 2012-08-17
- Lead Sponsor
- Agennix
- Target Recruit Count
- 20
- Registration Number
- NCT00093132
- Locations
- ๐บ๐ธ
Southwestern Medical Center, Dallas, Texas, United States
Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen
- Conditions
- Prostate CancerHormone Refractory Prostate Cancer
- First Posted Date
- 2003-10-06
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Agennix
- Registration Number
- NCT00069745
- Locations
- ๐บ๐ธ
University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
๐บ๐ธTexas Cancer Center at Medical City, Dallas, Texas, United States
๐ฉ๐ชMarienhospital II, Herne, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.